Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a post on LinkedIn:
“MARK YOUR CALENDARS – Pleased to invite you ALL to this BLOCKBUSTER session ESMO – European Society for Medical Oncology ESMO50 Annual meeting.
I’m deeply honored to chair what promises to be one of the most impactful sessions at ESMO 2025: ‘Accelerating Tumour Agnostic Therapies‘.
- Monday, October 20, 2025
- 08:30 – 10:00 CEST
- Hamburg Auditorium – CityCube A, Berlin
Co-Chairing with: The brilliant Niamh Coleman (Dublin, Ireland)
This blockbuster session brings together a unique constellation of perspectives that rarely converge in one room. We’re breaking down silos to accelerate the development and implementation of tumor-agnostic therapies through a truly multidisciplinary lens:
The Clinician’s Perspective (08:30-08:45): I’ll share insights from the frontlines of precision oncology, where molecular signatures are redefining how we treat patients.
The Statistician’s Perspective (08:45-09:00): Stefan Michiels (Villejuif, France) will tackle the complex statistical challenges in designing and analyzing tissue-agnostic trials.
The Molecular Biology, Pathologist’s Perspective (09:00-09:15): Fernando Lopez-Rios (Madrid, Spain) explores the critical role of molecular diagnostics in identifying agnostic targets.
The Regulator’s Perspective (09:15-09:30): Francesco Pignatti (Amsterdam, Netherlands) provides invaluable insights into regulatory pathways and approval considerations.
Interactive Question and Answer Session (09:30-10:00): 30 minutes of dynamic discussion where all perspectives converge.
See you in Berlin! (Coffee strongly recommended for this early morning blockbuster!)”
More posts featuring Vivek Subbiah on OncoDaily.